Shengmeng Peng

671 total citations
21 papers, 400 citations indexed

About

Shengmeng Peng is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Shengmeng Peng has authored 21 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Shengmeng Peng's work include Prostate Cancer Treatment and Research (7 papers), Epigenetics and DNA Methylation (5 papers) and Ubiquitin and proteasome pathways (4 papers). Shengmeng Peng is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Epigenetics and DNA Methylation (5 papers) and Ubiquitin and proteasome pathways (4 papers). Shengmeng Peng collaborates with scholars based in China and United States. Shengmeng Peng's co-authors include Xu Chen, Ming Huang, Qianghua Zhou, Ruihui Xie, Tianxin Lin, Yuelong Chen, Jingtong Zhang, Jian Huang, Yanjie Zhang and Jian Huang and has published in prestigious journals such as British Journal of Cancer, Advanced Science and Molecular Therapy.

In The Last Decade

Shengmeng Peng

21 papers receiving 397 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shengmeng Peng China 11 251 122 103 103 87 21 400
Rujun Mo China 13 282 1.1× 120 1.0× 115 1.1× 147 1.4× 36 0.4× 21 454
Junkichi Koinuma Japan 7 337 1.3× 96 0.8× 111 1.1× 81 0.8× 55 0.6× 19 446
Elia Farah United States 7 228 0.9× 187 1.5× 78 0.8× 123 1.2× 40 0.5× 8 358
Masashige Tendo Japan 11 188 0.7× 107 0.9× 148 1.4× 59 0.6× 82 0.9× 25 364
Daniela I. Paiva‐Oliveira Portugal 6 197 0.8× 77 0.6× 150 1.5× 101 1.0× 28 0.3× 7 328
Deepika Neelakantan United States 9 298 1.2× 56 0.5× 186 1.8× 180 1.7× 37 0.4× 11 463
Lingqiang Min China 10 227 0.9× 61 0.5× 112 1.1× 116 1.1× 33 0.4× 16 354
Tadahiko Nakagawa Japan 10 178 0.7× 64 0.5× 98 1.0× 65 0.6× 51 0.6× 25 331
Hubert Pakula United States 11 242 1.0× 166 1.4× 100 1.0× 142 1.4× 20 0.2× 17 415

Countries citing papers authored by Shengmeng Peng

Since Specialization
Citations

This map shows the geographic impact of Shengmeng Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengmeng Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengmeng Peng more than expected).

Fields of papers citing papers by Shengmeng Peng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengmeng Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengmeng Peng. The network helps show where Shengmeng Peng may publish in the future.

Co-authorship network of co-authors of Shengmeng Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Shengmeng Peng. A scholar is included among the top collaborators of Shengmeng Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengmeng Peng. Shengmeng Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peng, Shengmeng, Yongming Chen, Jie Zhou, et al.. (2025). SHCBP1 is a novel regulator of PLK1 phosphorylation and promotes prostate cancer bone metastasis. MedComm. 6(2). e70082–e70082. 2 indexed citations
2.
Li, Lingfeng, Bisheng Cheng, Yongming Chen, et al.. (2024). SERPINH1 modulates apoptosis by inhibiting P62 ubiquitination degradation to promote bone metastasis of prostate cancer. iScience. 27(8). 110427–110427. 3 indexed citations
3.
He, Haixia, Yanjie Zhang, Yi Li, et al.. (2024). PTBP1 Regulates DNMT3B Alternative Splicing by Interacting With RALY to Enhance the Radioresistance of Prostate Cancer. Advanced Science. 11(42). e2405997–e2405997. 4 indexed citations
4.
Peng, Shengmeng, et al.. (2024). FOXA1-dependent PUS1 regulates EIF3b stability in a non-enzymatic pathway mediating prostate cancer bone metastasis. International Journal of Biological Sciences. 20(11). 4566–4584. 6 indexed citations
5.
Peng, Shengmeng, Jin Li, Zean Li, et al.. (2023). SALL4 correlates with proliferation, metastasis, and poor prognosis in prostate cancer by affecting MAPK pathway. Cancer Medicine. 12(12). 13471–13485. 10 indexed citations
6.
Xiao, Kanghua, Shengmeng Peng, Junlin Lu, et al.. (2023). UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer. Cell Death and Disease. 14(7). 408–408. 27 indexed citations
7.
Zhou, Qianghua, Xu Chen, Kai Yao, et al.. (2023). TSPAN18 facilitates bone metastasis of prostate cancer by protecting STIM1 from TRIM32-mediated ubiquitination. Journal of Experimental & Clinical Cancer Research. 42(1). 195–195. 14 indexed citations
8.
Lu, Junlin, Kanghua Xiao, Shengmeng Peng, et al.. (2023). A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study. British Journal of Cancer. 129(7). 1166–1175. 2 indexed citations
9.
Chen, Yuelong, Ming Huang, Junlin Lu, et al.. (2023). Establishment of a prognostic model to predict chemotherapy response and identification of RAC3 as a chemotherapeutic target in bladder cancer. Environmental Toxicology. 39(2). 509–528. 4 indexed citations
10.
Huang, Ming, Wen Dong, Ruihui Xie, et al.. (2022). HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5‐WDR5‐dependent transcriptional program. Cancer Communications. 42(5). 447–470. 76 indexed citations
11.
Lai, Yiming, Shengmeng Peng, Yongming Chen, et al.. (2022). Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer. Frontiers in Oncology. 12. 957404–957404. 10 indexed citations
12.
Peng, Shengmeng, Xu Chen, Qianghua Zhou, et al.. (2022). UBE2S as a novel ubiquitinated regulator of p16 and β-catenin to promote bone metastasis of prostate cancer. International Journal of Biological Sciences. 18(8). 3528–3543. 33 indexed citations
13.
Chen, Yongming, Zefeng Shen, Shengmeng Peng, et al.. (2022). Bibliometric analysis of the global research development of bone metastases in prostate cancer: A 22-year study. Frontiers in Oncology. 12. 947445–947445. 5 indexed citations
14.
Zhou, Qianghua, Xu Chen, Haixia He, et al.. (2021). WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer. Theranostics. 11(10). 4809–4824. 44 indexed citations
15.
Zhang, Jingtong, Qianghua Zhou, Keji Xie, et al.. (2021). Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer. Journal of Experimental & Clinical Cancer Research. 40(1). 203–203. 57 indexed citations
16.
Xie, Ruihui, Xu Chen, Liang Cheng, et al.. (2020). NONO Inhibits Lymphatic Metastasis of Bladder Cancer via Alternative Splicing of SETMAR. Molecular Therapy. 29(1). 291–307. 61 indexed citations
17.
Lin, Chunhao, Shoumin Bai, Tao Du, et al.. (2019). <p>Polo-like kinase 3 is associated with poor prognosis and regulates proliferation and metastasis in prostate cancer</p>. Cancer Management and Research. Volume 11. 1517–1524. 13 indexed citations
18.
Li, Kaiwen, Qiong Wang, Xiaoming Ma, et al.. (2019). The comparison of transurethral versus suprapubic catheter after robot-assisted radical prostatectomy: a systematic review and meta-analysis. Translational Andrology and Urology. 8(5). 476–488. 5 indexed citations
19.
Bai, Shoumin, Dingjun Zhu, Kaiwen Li, et al.. (2019). Overexpression of malignant brain tumor domain containing protein 1 predicts a poor prognosis of prostate cancer. Oncology Letters. 17(5). 4640–4646. 6 indexed citations
20.
Peng, Shengmeng, Tao Du, Yiming Lai, et al.. (2018). Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression. Urologic Oncology Seminars and Original Investigations. 36(8). 366.e1–366.e9. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rujun Mo Breakdown of academic impact, for papers by Junkichi Koinuma Breakdown of academic impact, for papers by Elia Farah Breakdown of academic impact, for papers by Masashige Tendo Breakdown of academic impact, for papers by Daniela I. Paiva‐Oliveira Breakdown of academic impact, for papers by Deepika Neelakantan Breakdown of academic impact, for papers by Lingqiang Min Breakdown of academic impact, for papers by Tadahiko Nakagawa Breakdown of academic impact, for papers by Hubert Pakula
Rankless by CCL
2026